TCT-784 Evolution of TAVI over an seven-year period – a single-centre experience in 2,000 patients (TAVIK Registry)

During the first 30 days after the TAVI procedure, there was a non-significant trend towards reduction over time of the proportion of patients who experienced 1 or more event included in the VARC-2 early safety composite endpoint (cohort I: 16%, cohort IV:12%, p=0.068). The use of transfemoral implantations rise up significantly and there are significant improvements in cardiovascular mortality, device success, bleeding and vascular complications and moderate/severe valve regurgitation.